Analytical Power of LLE-HPLC-PDA-MS/MS in Drug Metabolism Studies: Identification of New Nabumetone Metabolites

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25310%2F13%3A39896453" target="_blank" >RIV/00216275:25310/13:39896453 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11160/13:10145888
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0731708513001167" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0731708513001167</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jpba.2013.03.006" target="_blank" >10.1016/j.jpba.2013.03.006</a>

Result language
angličtina
Original language name
Analytical Power of LLE-HPLC-PDA-MS/MS in Drug Metabolism Studies: Identification of New Nabumetone Metabolites
Original language description
Following oral administration, nabumetone is converted in the liver to 6-methoxy-2-naphthylacetic acid (6-MNA), the principal metabolite responsible for the NSAID effect. In this study, a new, as yet unreported phase 1 metabolite was discovered within the evaluation of nabumetone metabolism by human and rat liver microsomal fractions. Extracts from the biomatrices were subjected to chiral LLE-HPLC-PDA and achiral LLE-UHPLC-MS/MS analyses to elucidate the chemical structure of this metabolite. UHPLC-MS/MS experiments detected the presence of a structure corresponding to elemental composition C15H16O3, which was tentatively assigned as a hydroxylated nabumetone. Identical nabumetone and HO-nabumetone UV spectra obtained from the FDA detector ruled out the presence of the hydroxy group in the aromatic moiety of nabumetone. Hence, the most likely structure of the new metabolite was 4-(6-methoxy-2-naphthyl)-3-hydroxybutan-2-one (3-hydroxy nabumetone). To confirm this structure, the standard
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CB - Analytical chemistry, separation
OECD FORD branch
—

Project
<a href="/en/project/GAP207%2F10%2F2048" target="_blank" >GAP207/10/2048: Chiral Quinazoline Alkaloids: Potential Prototypes of Novel Antiasthmatics and Organocatalysts</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)